Rodrique Mortel

1.4k total citations
17 papers, 1.0k citations indexed

About

Rodrique Mortel is a scholar working on Obstetrics and Gynecology, Oncology and Reproductive Medicine. According to data from OpenAlex, Rodrique Mortel has authored 17 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Obstetrics and Gynecology, 6 papers in Oncology and 5 papers in Reproductive Medicine. Recurrent topics in Rodrique Mortel's work include Endometrial and Cervical Cancer Treatments (8 papers), Ovarian cancer diagnosis and treatment (5 papers) and Cervical Cancer and HPV Research (3 papers). Rodrique Mortel is often cited by papers focused on Endometrial and Cervical Cancer Treatments (8 papers), Ovarian cancer diagnosis and treatment (5 papers) and Cervical Cancer and HPV Research (3 papers). Rodrique Mortel collaborates with scholars based in United States. Rodrique Mortel's co-authors include B. Bundy, Jonathan S. Berek, G A Omura, Stephen Curry, Howard D. Homesley, Alexander Sedlis, J. S. Berek, Antoine E. Jahshan, Edgardo Yordan and George C. Lewis and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Rodrique Mortel

17 papers receiving 983 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rodrique Mortel United States 12 533 500 427 285 187 17 1.0k
J A Blessing United States 10 720 1.4× 735 1.5× 406 1.0× 193 0.7× 125 0.7× 18 1.1k
J.Taylor Wharton United States 15 399 0.7× 417 0.8× 394 0.9× 241 0.8× 217 1.2× 36 898
A P Heintz Netherlands 8 759 1.4× 1.2k 2.4× 302 0.7× 410 1.4× 275 1.5× 12 1.6k
Uğur Saygılı Türkiye 19 463 0.9× 397 0.8× 231 0.5× 140 0.5× 131 0.7× 56 937
Susan Zweizig United States 15 429 0.8× 397 0.8× 190 0.4× 155 0.5× 196 1.0× 32 925
Derek Cruickshank United Kingdom 16 498 0.9× 443 0.9× 205 0.5× 76 0.3× 229 1.2× 37 888
Malkasian Gd United States 16 495 0.9× 228 0.5× 227 0.5× 71 0.2× 121 0.6× 33 739
Mario Beiner Israel 23 713 1.3× 638 1.3× 271 0.6× 257 0.9× 216 1.2× 46 1.3k
Maria Giovanna Salerno Italy 14 438 0.8× 501 1.0× 336 0.8× 172 0.6× 143 0.8× 26 854
Kuan-Chong Chao Taiwan 18 310 0.6× 400 0.8× 253 0.6× 118 0.4× 121 0.6× 61 923

Countries citing papers authored by Rodrique Mortel

Since Specialization
Citations

This map shows the geographic impact of Rodrique Mortel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rodrique Mortel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rodrique Mortel more than expected).

Fields of papers citing papers by Rodrique Mortel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rodrique Mortel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rodrique Mortel. The network helps show where Rodrique Mortel may publish in the future.

Co-authorship network of co-authors of Rodrique Mortel

This figure shows the co-authorship network connecting the top 25 collaborators of Rodrique Mortel. A scholar is included among the top collaborators of Rodrique Mortel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rodrique Mortel. Rodrique Mortel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lacey, J., Louise A. Brinton, Willard A. Barnes, et al.. (1999). Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas.. PubMed. 8(12). 1079–85. 79 indexed citations
2.
Sturgeon, Susan R., Mark E. Sherman, Robert J. Kurman, et al.. (1998). Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors.. PubMed. 7(3). 231–5. 9 indexed citations
3.
Homesley, Howard D., B. Bundy, Alexander Sedlis, et al.. (1991). Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (A Gynecologic Oncology Group Study). American Journal of Obstetrics and Gynecology. 164(4). 997–1004. 230 indexed citations
4.
Omura, G A, et al.. (1989). Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.. Journal of Clinical Oncology. 7(4). 457–465. 256 indexed citations
5.
Malkasian, George D., Robert C. Knapp, Philip T. Lavin, et al.. (1988). Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant disease. American Journal of Obstetrics and Gynecology. 159(2). 341–346. 171 indexed citations
6.
Stehman, Frederick B., B. Bundy, Henry Keys, et al.. (1988). A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. American Journal of Obstetrics and Gynecology. 159(1). 87–94. 50 indexed citations
7.
Manetta, Alberto, et al.. (1988). Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma.. PubMed. 9(3). 222–7. 7 indexed citations
8.
Asbury, Robert F., John A. Blessing, Rodrique Mortel, Howard D. Homesley, & John H. Malfetano. (1987). Aminothiadiazole (NSC #4728) in Patients With Advanced Cervical Carcinoma A Phase II Study of the Gynecologic Oncology Group. American Journal of Clinical Oncology. 10(4). 299–301. 6 indexed citations
9.
Houts, Peter S., Charles W. Whitney, Rodrique Mortel, & Mary J. Bartholomew. (1986). Former Cancer Patients as Counselors of Newly Diagnosed Cancer Patients<xref ref-type="fn" rid="FN1">2</xref>. JNCI Journal of the National Cancer Institute. 76(5). 793–6. 39 indexed citations
10.
Chung, C.K., John A. Stryker, William A. Nahhas, & Rodrique Mortel. (1981). The role of adjunctive radiotherapy for stage I endometrial carcinoma: Preoperative vs postoperative irradiation. International Journal of Radiation Oncology*Biology*Physics. 7(10). 1429–1435. 10 indexed citations
11.
Curry, Stephen L., et al.. (1981). The role of prostaglandins in the excessive nausea and vomiting after intravascular cis-platinum therapy. Gynecologic Oncology. 12(1). 89–91. 18 indexed citations
12.
Sall, Sanford, Philip J. DiSaia, C. Paul Morrow, et al.. (1979). A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. American Journal of Obstetrics and Gynecology. 135(5). 647–650. 26 indexed citations
13.
Nahhas, William A., Arthur B. Abt, & Rodrique Mortel. (1977). Stage I B glassy cell carcinoma of the cervix with ovarian metastases. Gynecologic Oncology. 5(1). 87–91. 14 indexed citations
14.
Lewis, George C., Rodrique Mortel, & Nelson H. Slack. (1977). Endometrial cancer.Therapeutic decision and the staging process in “early” disease. Cancer. 39(S2). 959–966. 24 indexed citations
15.
Mortel, Rodrique, Joseph C. Allegra, Laurence M. Demers, et al.. (1977). Plasma prostaglandins across the tumor bed of patients with gynecologic malignancy. Cancer. 39(5). 2201–2203. 6 indexed citations
16.
Lipton, Allan, et al.. (1976). Urinary polyamine levels in patients with localized malignancy. Cancer. 38(3). 1344–1347. 23 indexed citations
17.
Lewis, George C., Nelson H. Slack, Rodrique Mortel, & Irwin D. J. Bross. (1974). Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecologic Oncology. 2(2-3). 368–376. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J A Blessing Breakdown of academic impact, for papers by J.Taylor Wharton Breakdown of academic impact, for papers by A P Heintz Breakdown of academic impact, for papers by Uğur Saygılı Breakdown of academic impact, for papers by Susan Zweizig Breakdown of academic impact, for papers by Derek Cruickshank Breakdown of academic impact, for papers by Malkasian Gd Breakdown of academic impact, for papers by Mario Beiner Breakdown of academic impact, for papers by Maria Giovanna Salerno Breakdown of academic impact, for papers by Kuan-Chong Chao
Rankless by CCL
2026